Biological Evaluation of Isoniazid Derivatives as an Anticancer Class
Abstract
Share and Cite
RODRIGUES, F.A.R.; OLIVEIRA, A.C.A.; CAVALCANTI, B.C.; PESSOA, C.; PINHEIRO, A.C.; DE SOUZA, M.V.N. Biological Evaluation of Isoniazid Derivatives as an Anticancer Class. Sci. Pharm. 2014, 82, 21-28. https://doi.org/10.3797/scipharm.1307-25
RODRIGUES FAR, OLIVEIRA ACA, CAVALCANTI BC, PESSOA C, PINHEIRO AC, DE SOUZA MVN. Biological Evaluation of Isoniazid Derivatives as an Anticancer Class. Scientia Pharmaceutica. 2014; 82(1):21-28. https://doi.org/10.3797/scipharm.1307-25
Chicago/Turabian StyleRODRIGUES, Felipe A. R., Augusto C. A. OLIVEIRA, Bruno C. CAVALCANTI, Claudia PESSOA, Alessandra C. PINHEIRO, and Marcus V. N. DE SOUZA. 2014. "Biological Evaluation of Isoniazid Derivatives as an Anticancer Class" Scientia Pharmaceutica 82, no. 1: 21-28. https://doi.org/10.3797/scipharm.1307-25
APA StyleRODRIGUES, F. A. R., OLIVEIRA, A. C. A., CAVALCANTI, B. C., PESSOA, C., PINHEIRO, A. C., & DE SOUZA, M. V. N. (2014). Biological Evaluation of Isoniazid Derivatives as an Anticancer Class. Scientia Pharmaceutica, 82(1), 21-28. https://doi.org/10.3797/scipharm.1307-25